The short version of insulin-like growth factor 1 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-09 and is reviewed periodically as new material appears.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
The first 16 months of the MD program, the preclerkship phase, consists of fundamental scientific and medical coursework. Multi-semester courses include bioethics and service learning. This is followed by a 12-month clinical phase that includes clerkships and preparation for and completion of the United States Medical Licensing Examination (USMLE) Step 1. Clerkships are followed by completion of the USMLE Step 2 exam. The final 18 months of medical school include clinical electives, increased clinical duties, and a research capstone project. In addition to Jacobi and Montefiore hospitals, medical students can train in medical facilities such as the VA Bronx Healthcare System and Bronx Psychiatric Center. Students may also volunteer at the Einstein Community Health Outreach (ECHO) Free Clinic, which provides care to those without health insurance. Founded in 1999, ECHO was the first such clinic in New York City and one of the first in the United States.
In clinical practice, this means that it takes 4 to 5 times the half-life for a drug's serum concentration to reach steady state after regular dosing is started, stopped, or the dose changed. So, for example, digoxin has a half-life (or t1/2) of 24–36 h; this means that a change in the dose will take the best part of a week to take full effect. For this reason, drugs with a long half-life (e.g., amiodarone, elimination t1/2 of about 58 days) are usually started with a loading dose to achieve their desired clinical effect more quickly.
Chemical ligation is the chemoselective condensation of unprotected peptide segments enabled by the formation of a non-native bond at the ligation site. Chemical ligation is usually carried out in aqueous solution. Multiple consecutive chemical ligation reactions can be used to make proteins of the typical size found in nature, i.e. with polypeptide chains containing 200–300 amino acids, produced by total synthesis.
=== Legal status === Around the world, codeine is, contingent on its concentration, a Schedule II and III drug under the Single Convention on Narcotic Drugs. In Australia, Canada, New Zealand, Sweden, the United Kingdom, the United States and many other countries, codeine is regulated under various narcotic control laws. In some countries, it is available without a medical prescription in combination preparations from licensed pharmacists in doses up to 20 mg, or 30 mg when sold combined with 500 mg paracetamol. As of 2015, of the European Union member states, 11 countries (Bulgaria, Cyprus, Denmark, Estonia, Ireland, Latvia, Lithuania, Malta, Poland, Romania, and Slovenia) allow the sale of OTC codeine solid dosage forms.
Sources: en.wikipedia.org
=== Books === Separation Processes (1971); 2nd edition (1980) Freeze Drying of Foods (1971) The University of California: Creating, Nurturing, and Maintaining Academic Quality in a Public University Setting (2018)
Wallerian degeneration is an active process of degeneration that results when a nerve fiber is cut or crushed and the part of the axon distal to the injury (which in most cases is farther from the neuron's cell body) degenerates. A related process of dying back or retrograde degeneration known as 'Wallerian-like degeneration' occurs in many neurodegenerative diseases, especially those where axonal transport is impaired such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Primary culture studies suggest that a failure to deliver sufficient quantities of the essential axonal protein NMNAT2 is a key initiating event. Some studies also have found irreversible electroporation, a potential clinical treatment being researched in porcine models to determine efficacy to treat spinal cord injuries, has contributed to Wallerian degeneration of lumbar nerve roots. Wallerian degeneration occurs after axonal injury in both the peripheral nervous system (PNS) and central nervous system (CNS). It occurs in the section of the axon distal to the site of injury and usually begins within 24–36 hours of a lesion. Prior to degeneration, the distal section of the axon tends to remain electrically excitable. After injury, the axonal skeleton disintegrates, and the axonal membrane breaks apart. Axonal degeneration is followed by degradation of the myelin sheath and infiltration by macrophages. The macrophages, accompanied by Schwann cells, serve to clear the debris from the degeneration.
Seeing her escape avenue, Owens agreed and vacuumed the house to indicate her acquiescence to becoming an extended member of the family. Later that day, Owens escaped from a launderette she and Rose had entered and returned home. Although initially too ashamed to divulge what had happened, when her mother noted the welts, bruises and exposed subcutaneous tissues on her daughter's body, Owens burst into tears and confided her ordeal. Owens' mother immediately reported her daughter's story to police, and the Wests were arrested and charged with assault, indecent assault, actual bodily harm and rape. The case was tried at Gloucester Magistrates Court on 12 January 1973, but by this date Owens had decided she could not face the ordeal of giving testimony. All charges pertaining to her ordeal were dropped, and the Wests agreed to plead guilty to the reduced charges of indecent assault and causing actual bodily harm. Rose and Fred were each fined £50 (equivalent to £1,000 in 2025) and the couple were allowed to walk free. When Owens heard this news, she attempted suicide.
=== Pharmacodynamics === Ephenidine and related diarylethylamines have been studied in vitro as treatments for neurotoxic injuries, and are antagonists of the NMDA receptor (Ki = 66.4 nM for ephenidine). Ephenidine also possesses weaker affinity for dopamine and norepinephrine transporters (379 nM and 841 nM, respectively) as well as σ1R (629 nM) and σ2R (722 nM) binding sites.
Horn instead of Marvel Entertainment CEO Isaac Perlmutter, and the creative committee began having only "nominal" input on the films. They continued to consult on Marvel Television productions, which remained under Perlmutter's control. All key film decisions moving forward were to be made by Feige, D'Esposito, and executive vice president Victoria Alonso. The studio went on to establish the Marvel Studios Parliament, a "brain trust" of long-time executives at the company who help to elevate each other's projects where possible. In November 2017, Feige said the Phase Three crossover films Avengers: Infinity War (2018) and Avengers: Endgame (2019) would provide a definitive conclusion to the films thus far and begin a new period for the franchise. He later said Phases One, Two, and Three were collectively known as "The Infinity Saga".
Sources: en.wikipedia.org
==== Tolerance ==== Chronic use of benzodiazepines, such as chlordiazepoxide, leads to the development of tolerance, with a decrease in number of benzodiazepine binding sites in mice forebrains. The Committee of Review of Medicines, who carried out an extensive review of benzodiazepines including chlordiazepoxide, found—and were in agreement with the US Institute of Medicine and the conclusions of a study carried out by the White House Office of Drug Policy and the US National Institute on Drug Abuse—that there was little evidence that long-term use of benzodiazepines was beneficial in the treatment of insomnia due to the development of tolerance. Benzodiazepines tended to lose their sleep-promoting properties within 3 to 14 days of continuous use, and in the treatment of anxiety the committee found that there was little convincing evidence that benzodiazepines retained efficacy in the treatment of anxiety after four months' continuous use due to the development of tolerance.
=== Cancer === Heejin et al. showed that trimebutine is effective at stopping ovarian cancer cells from growing in vitro. This effect is believed to be exerted through G0/G1 phase switch arrest, voltage-gated calcium channels and calcium-activated potassium channels inhibition and suppressing Wnt, Notch and Hedgehog pathways. Yi-pu Fan et al. found that trimebutine can inhibit glioma and glioblastoma cells from proliferating by promoting apoptosis and downregulation of Bcl-2, thereby upregulating Bax pro-apoptotic factor.
=== Reform in 1934 === The Local Government Act 1929 imposed the duty on county councils of reviewing the districts within their administrative county so as to form more efficient units of local government. In general, this meant the merging of small or lightly populated areas into larger units. A review was carried in Cumberland in 1934. The following table lists the urban and rural districts before and after the changes.
Alton Meister (1922–1995) was an American biochemist who made pioneering contributions to the study of glutathione metabolism. Alton Meister was born in New York City to Morris Meister and Florence Glickstein Meister. He received an undergraduate degree from Harvard University and an MD from Cornell University Medical College (now Weill Cornell Medical College). He then moved to the National Cancer Institute at the National Institutes of Health in Bethesda, Maryland. He remained there until 1955 when he became Chairman of the Department of Biochemistry at Tufts University. Meister returned to Cornell University Medical College in 1967 and served as chairman of its biochemistry department until 1991. He died in 1995 at the age of 72.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.